CHARLESTON, S.C.--(BUSINESS WIRE)--
Aeterna Zentaris Inc. (AEZS) (AEZS.TO) (the “Company”) will announce the top-line results of the ZoptEC Phase 3 clinical study of Zoptrex™ (zoptarelin doxorubicin) in women with locally advanced, recurrent or metastatic endometrial cancer prior to the commencement of trading on Monday, May 1, 2017.
The Company will host a conference call to discuss the results of the ZoptEC Phase 3 clinical study of Zoptrex™ on Monday, May 1, 2017, at 8:30 AM, Eastern Time. Participants may access the conference call by using the following number: 201-689-8029, Confirmation 13660857.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. We are engaged in drug development activities and in the promotion of products for others. We recently completed Phase 3 studies of two internally developed compounds. The focus of our business development efforts is the acquisition of licenses to products that are relevant to our therapeutic areas of focus. We also intend to license out certain commercial rights of internally developed products to licensees in non-US territories where such out-licensing would enable us to ensure development, registration and launch of our product candidates. Our goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful commercial presence and growth, while consistently delivering value to our shareholders, employees and the medical providers and patients who will benefit from our products. For more information, visit www.aezsinc.com.